Skip to main content

Dr. Daniel W. Sherbenou, MD, PHD

Hematology & Oncology (Hematology & Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
17
In the NPI registry since
2009
Medicare patients seen, 2024
211

Licensed in Colorado since 2011, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2009Medical school: Oregon Health Sciences University School of Medicine
  • 2009Registered with an NPI (national billing number; not a license date)

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology & Oncology Physician primary
    CO license DR.0055891 (first issued 2015; active)
  • Hematology (Internal Medicine) Physician
    CO license DR.0055891 (first issued 2015; active)
  • Hepatology Physician
    CO license 0050375 (first issued 2011; active)

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology & Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
211
Services billed
504
Patients’ average age
72
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 40-54 minutes20479
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes18337
Hospital discharge day management, 30 minutes or less2120

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 4 companies reported 5 payments worth $1,545 in total to this clinician.

By type
Consulting Fee$1,170
Food and Beverage$375

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Dec 5, 2025Janssen Biotech, Inc.
Dec 5, 2025
Consulting Fee$1,170

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Colorado →

Industry-funded research

Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $112,720 in research payments for these studies, mostly to the institutions running them.

  • Phase I II Cevostamab in Prior BCMA Exposed r r Multiple Myeloma patients
    Genentech, Inc.
  • Ph I of FcRH5 CD3 in multiple myeloma
    Genentech, Inc.
  • A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amylo…
    Janssen Research & Development, LLC
  • A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)
    Celgene Corporation

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Aurora

Sources

NPI registry (CMS NPPES, November 2026; record last updated April 17, 2023), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1104053438. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.